stockrow
Monday 9 November 2026
Export PEPG’s income statement to Excel — free account
PepGen, Inc.
PEPG- EPS
- +62.9%
- Free cash flow
- +33.0%
Quarter to June 2026, against a year earlier
2.47
0.15
+6.47%
Follow PEPG
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | (1) | (2) | (27) | (65) | (79) | (91) | (90) | (72) | +101.3% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | (1) | (2) | (27) | (69) | (79) | (90) | (90) | (72) | +101.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (0.06) | (4.69) | (30.28) | (4.42) | (3.30) | (2.85) | (2.12) | (1.31) | +81.1% | ||||||
| Cash flow | — | — | — | (0.04) | (1.90) | (25.08) | (3.79) | (2.90) | (2.61) | (1.93) | (1.00) | +91.3% | ||||||
| Capex | — | — | — | 0.00 | (0.01) | (0.55) | (0.24) | (0.11) | (0.02) | (0.01) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (0.04) | (1.91) | (25.64) | (4.03) | (3.01) | (2.62) | (1.94) | (1.00) | +91.4% | ||||||
| Book value | — | — | — | 0.17 | (7.31) | (35.61) | 11.49 | 4.56 | 3.76 | 3.49 | 1.73 | +65.1% | ||||||
| Shares, m | — | — | — | 22 | 1 | 1 | 16 | 24 | 32 | 42 | 54 | +11.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (1) | (2) | (23) | (59) | (69) | (82) | (82) | (69) | +112.6% | |||||
| Capex | — | — | — | 0 | 0 | 0 | (4) | (3) | 0 | 0 | 0 | +44.5% | ||||||
| Free cash flow | — | — | — | (1) | (2) | (23) | (63) | (72) | (83) | (82) | (70) | +112.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 3 | 9 | 130 | 167 | 95 | 107 | 138 | 111 | +85.0% | |||||
| Net debt | — | — | — | (3) | (10) | (133) | (182) | (110) | (120) | (148) | (117) | +86.8% | ||||||
| Shareholders’ equity | — | — | — | 4 | (6) | (32) | 180 | 108 | 119 | 147 | 120 | +83.5% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (54.96) | (35.36) | (38.28) | (43.62) | (61.23) | (55.21) | (59.06) | (55.2) pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (2,076.25) | 0.0 pt | ||||||
| ROE | — | — | — | 0.00 | 327.08 | 141.93 | (93.67) | (54.59) | (79.26) | (67.39) | (75.45) | (67.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 31 | 45 | 64 | 81 | 56 | — | +15.9% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
PepGen, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MDWD MediWound Ltd. | $184.0M | — (loss-making) | — (loss-making) | −45.83% (below 0%: shrinking) | n/m | −49.90% (below 0%: shrinking) | 10.90% | (305.89%) | Compare |
| WHWK Whitehawk Therapeutics, Inc. | $178.4M | — (loss-making) | — (loss-making) | +33.48% (above 0%: growing) | n/m | +72.57% (above 0%: growing) | 89.36% | 0.00% | Compare |
| PEPG PepGen, Inc. | $171.1M | — (loss-making) | — | — | n/m | +33.02% (above 0%: growing) | 0.00% | 0.00% | |
| CNTN Canton Strategic Holdings, Inc. | $164.1M | — (loss-making) | — | — | n/m | −600.39% (below 0%: shrinking) | 100.00% | (80.37%) | Compare |
| ZNTL Zentalis Pharmaceuticals, Inc. | $162.8M | — (loss-making) | — (loss-making) | — | n/m | −9.06% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IPHA Innate Pharma S.A. Sponsored ADR | $160.9M | — (loss-making) | — | +246.29% (above 0%: growing) | +106.08% (above 0%: growing) | −929.03% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ORMP Oramed Pharmaceuticals Inc. | $160.6M | 0.9× | 0.9× | +193.26% (above 0%: growing) | +493.75% (above 0%: growing) | +94.29% (above 0%: growing) | 0.65% | 0.00% | Compare |
| ALXO ALX Oncology Holdings Inc. | $159.7M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +31.65% (above 0%: growing) | 0.00% | 0.00% | Compare |
| STRO Sutro Biopharma, Inc. | $159.5M | — (loss-making) | — (loss-making) | −84.57% (below 0%: shrinking) | n/m | +14.55% (above 0%: growing) | 100.00% | (303.77%) | Compare |
| Median of peers | $161.8M | — | — | −6.17% | — | +2.74% | 50.13% | 0.00% |
Pay and ownership Proxy statement filed 28 April 2026
Ownership
Directors and executive officers, together
1.30%
Entities Affiliated with RA Capital
29.10%
Oxford Science Enterprises plc
7.20%
Commodore Capital LP
5.10%
Viking Global Investors and affiliates
5.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement